15:28 uur 10-03-2020

c-LEcta neemt een nieuwe industriële partner aan en zet zijn ontwikkeling tot een productbedrijf met succes voort

  • Uitbreiding van samenwerking met de sector op het gebied van procesontwikkeling
  • Samenwerking met een van ‘s werelds grootste leveranciers van geuren en smaken
  • Ten minste twee nieuwe productlanceringen gepland voor 2020
  • Uitbreiding van de productportfolio in de doelmarkten voedsel- en farmaceutische sector

LEIPZIG, Duitsland – (BUSINESS WIRE) – c-LEcta, een toonaangevende innovator en leverancier van biotechnologische producten voor gereguleerde markten zoals food en pharma, gaat een ontwikkelingspartnerschap aan met het beursgenoteerde bedrijf Symrise. Symrise AG, opgericht in 2003, is een van ‘s werelds toonaangevende leveranciers van geuren en smaken

c-LEcta takes on new industrial partner and successfully continues its development into a product company

  • Expansion of cooperation with industry in the area of process development
  • Cooperation with one of the world’s largest suppliers of fragrances and flavors
  • At least two new product launches planned for 2020
  • Expansion of the product portfolio in the target markets food and pharmaceutical industry

LEIPZIG, Germany–(BUSINESS WIRE)– c-LEcta, a leading innovator and supplier of biotechnological products for regulated markets like food and pharma, is entering into a development partnership with the MDax-listed company Symrise. Founded in 2003, Symrise AG is one of the world’s leading suppliers of fragrances and flavors.

The development of an enzymatic process for the production of a flavoring agent is the focus of the collaboration. c-LEcta thus strengthens its role as a partner to the food industry. “Such collaborations with the goal of jointly developing and marketing new products are an important part of our corporate strategy. They enable us to evolve future business and thus make an important contribution to our growth. We are very pleased about the new cooperation with Symrise,” commented Dr. Marc Struhalla, CEO and co-founder of c-LEcta. The company is currently engaged in seven active development collaborations with industry. “This shows that c -LEcta is a sought-after partner of industry when it comes to expertise and efficiency in the development of new biotechnological processes,” Struhalla added.

The second pillar of growth are proprietary product developments. c-LEcta develops and markets two categories of biotechnological products: industrial enzymes and biotechnologically produced ingredients. c-LEcta’s enzyme products are used as process auxiliaries in industrial production. The goal, for example, is to make production processes more efficient, or to make them possible in the first place. Thus, products can be improved and resources saved.

The Ingredients products are low-molecular compounds, which are very often of natural origin. They are used as components or additives in industrially manufactured products. With the help of c-LEcta’s patented bioinformatics platform, such ingredients can be produced particularly efficiently and purely. By adding the ingredients, high-quality products of the food and pharmaceutical industry can be produced at lower costs.

This year, at least two further product launches are planned to expand the portfolio for the target markets food and pharmaceutical industries. “Our well-filled product pipeline, the diverse applications of our products and worldwide sales markets offer good prospects for long-term growth. The two pillars of our strategy, partnerships and own products, complement each other, so that we can optimally exploit and further develop our innovative technology platform,” emphasizes Thomas Pfaadt, CFO of c-LEcta.

About c-LEcta

c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 70 people.

c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.


cometis AG

Matthias Kunz

Phone: +49 (0) 611 – 205855 – 64

Fax: +49 (0) 611 – 205855 – 66

e-mail: kunz@cometis.de

Check out our twitter: @NewsNovumpr